dextromethorphan + propofol

Dextromethorphan + propofol is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Dextromethorphan is a non-opioid antitussive (cough suppressant) that acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist and also inhibits serotonin reuptake, which can contribute to central nervous system effects and, at high doses or in combination with other serotonergic drugs, may cause serotonin syndrome[3][5][1]. Propofol is an intravenous sedative-hypnotic agent used for the induction and maintenance of anesthesia or sedation; it works mainly by potentiating the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors[2][6]. When combined, these drugs can have additive central nervous system depressant effects and may increase the risk of adverse reactions such as respiratory depression or enhanced sedation[2][10]. This combination does not represent a marketed fixed-dose product but may be encountered in clinical scenarios involving polypharmacy or overdose.